These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 24733102

  • 1. [Clinical significance of and treatment options for increased lipoprotein(a)].
    Zsíros N, Paragh G, Harangi M.
    Orv Hetil; 2014 Apr 20; 155(16):607-14. PubMed ID: 24733102
    [Abstract] [Full Text] [Related]

  • 2. Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).
    Grützmacher P, Öhm B, Szymczak S, Dorbath C, Brzoska M, Kleinert C.
    Clin Res Cardiol Suppl; 2017 Mar 20; 12(Suppl 1):22-26. PubMed ID: 28233269
    [Abstract] [Full Text] [Related]

  • 3. Latest developments in the treatment of lipoprotein (a).
    Bos S, Yayha R, van Lennep JE.
    Curr Opin Lipidol; 2014 Dec 20; 25(6):452-60. PubMed ID: 25318824
    [Abstract] [Full Text] [Related]

  • 4. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
    Vogt A.
    Clin Res Cardiol Suppl; 2017 Mar 20; 12(Suppl 1):12-17. PubMed ID: 28185213
    [Abstract] [Full Text] [Related]

  • 5. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
    Kassner U, Schlabs T, Rosada A, Steinhagen-Thiessen E.
    Atheroscler Suppl; 2015 May 20; 18():263-7. PubMed ID: 25936335
    [Abstract] [Full Text] [Related]

  • 6. Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy.
    Sbrana F, Bigazzi F, Corciulo C, Dal Pino B.
    Eur J Prev Cardiol; 2024 Jun 03; 31(8):e62-e64. PubMed ID: 38470832
    [No Abstract] [Full Text] [Related]

  • 7. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z.
    Nutr Metab Cardiovasc Dis; 2013 Sep 03; 23(9):799-807. PubMed ID: 23932901
    [Abstract] [Full Text] [Related]

  • 8. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W.
    Atheroscler Suppl; 2017 Nov 03; 30():180-186. PubMed ID: 29096835
    [Abstract] [Full Text] [Related]

  • 9. Ongoing challenges for pharmacotherapy for dyslipidemia.
    Pisaniello AD, Scherer DJ, Kataoka Y, Nicholls SJ.
    Expert Opin Pharmacother; 2015 Feb 03; 16(3):347-56. PubMed ID: 25476544
    [Abstract] [Full Text] [Related]

  • 10. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U, Milton M, Stoellner D, Rader D, Gordon B, Polk D, Waldmann E, Parhofer KG, Moriarty PM.
    Atheroscler Suppl; 2015 May 03; 18():180-6. PubMed ID: 25936324
    [Abstract] [Full Text] [Related]

  • 11. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R, Pro(a)LiFe Study Group*.
    Circulation; 2013 Dec 17; 128(24):2567-76. PubMed ID: 24056686
    [Abstract] [Full Text] [Related]

  • 12. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
    Guijarro C, Ruilope LM.
    Med Clin (Barc); 2015 Jul 20; 145(2):67-9. PubMed ID: 26004275
    [No Abstract] [Full Text] [Related]

  • 13. Novel strategies for managing dyslipidemia: treatment beyond statins.
    Ling H, Burns TL, Hilleman DE.
    Postgrad Med; 2012 Nov 20; 124(6):43-54. PubMed ID: 23322138
    [Abstract] [Full Text] [Related]

  • 14. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
    Klingel R, Heibges A, Fassbender C, Pro(a)LiFe-Study Group.
    Clin Res Cardiol Suppl; 2017 Mar 20; 12(Suppl 1):38-43. PubMed ID: 28185214
    [Abstract] [Full Text] [Related]

  • 15. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
    Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordestgaard BG, Maerz W, Noureen A, Schmidt K, Kronenberg F, Heibges A, Klingel R, Pro(a)LiFe-Study Group.
    Arterioscler Thromb Vasc Biol; 2016 Sep 20; 36(9):2019-27. PubMed ID: 27417585
    [Abstract] [Full Text] [Related]

  • 16. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L.
    Orv Hetil; 2014 Jan 12; 155(2):62-8. PubMed ID: 24389322
    [Abstract] [Full Text] [Related]

  • 17. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
    Ezhov MV, Safarova MS, Afanasieva OI, Pogorelova OA, Tripoten MI, Adamova IY, Konovalov GA, Balakhonova TV, Pokrovsky SN.
    Atheroscler Suppl; 2015 May 12; 18():163-9. PubMed ID: 25936321
    [Abstract] [Full Text] [Related]

  • 18. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.
    Schmitz G, Orsó E.
    Clin Res Cardiol Suppl; 2015 Apr 12; 10(Suppl 1):21-5. PubMed ID: 25708587
    [Abstract] [Full Text] [Related]

  • 19. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.
    Hajhosseiny R, Sabir I, Khavandi K, Wierzbicki AS.
    Clin Pharmacol Ther; 2014 Jul 12; 96(1):64-73. PubMed ID: 24699033
    [Abstract] [Full Text] [Related]

  • 20. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R, Heibges A, Fassbender C.
    Atheroscler Suppl; 2015 May 12; 18():35-40. PubMed ID: 25936302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.